Structure Therapeutics (GPCR) stock and Metsera (MTSR) stock soar as Eli Lilly (LLY) reports promising Phase 3 results for ...

Viking (VKTX) stock, Structure (GPCR) stock and others surge after Pfizer’s obesity drug setback. Read more here.

Metsera Inc. also stands to benefit, as while its oral GLP-1 is a bit behind, initial data is expected in the fourth quarter of this year. Structure Therapeutics' stock (GPCR) shot up 12.4% in ...

If any further evidence were needed for the insatiable investor appetite for companies with obesity assets, look no further than New York start-up Metsera. After emerging from stealth with a $290 ...

Shares of Viking Therapeutics, Altimmune, Structure Therapeutics and Metsera — all of which have weight loss drugs in clinical testing — rose in trading Monday.

As per Inc42 data, 20 startups are in various stages of undertaking their IPO preparations at the outset of 2025 Key factors that are likely to contribute to the public listing mania in 2025 are ...

Early-stage publicly traded obesity biotechs Metsera and Viking Therapeutics sport market caps in the $3 billion range. In October, Renaud hired Scott Wasserman, who served as Amgen’s first ...

Pfizer (PFE) stock was up on Monday despite the pharmaceutical company ending the clinical trial of its once-daily GLP-1 weight loss pill, danuglipron. The company had to cut this trial off early ...

BofA analyst Tim Anderson notes Pfizer (PFE) announced danuglipron, an oral GLP-1 obesity, is being discontinued, following a case of liver injury seen in the phase 1 study. The firm points out ...